Xanthine Derivatives

2020 Jul 18. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–.

Atomoxetine Therapy and CYP2D6 Genotype

Dean L.

2015 Sep 10 [updated 2020 Jun 29]. In: Pratt VM, McLeod HL, Rubinstein WS, Scott SA, Dean LC, Kattman BL, Malheiro AJ, editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012–.

Mutations in DNMT1 cause autosomal dominant cerebellar ataxia, deafness and narcolepsy.

Winkelmann J, Lin L, Schormair B, Kornum BR, Faraco J, Plazzi G, Melberg A, Cornelio F, Urban AE, Pizza F, Poli F, Grubert F, Wieland T, Graf E, Hallmayer J, Strom TM, Mignot E.

Hum Mol Genet. 2012 May 15;21(10):2205-10. doi: 10.1093/hmg/dds035.

Differential effects of dopaminergic medication on basic motor performance and executive functions in Parkinson's disease.

Michely J, Barbe MT, Hoffstaedter F, Timmermann L, Eickhoff SB, Fink GR, Grefkes C.

Neuropsychologia. 2012 Aug;50(10):2506-14. doi: 10.1016/j.neuropsychologia.2012.06.023.

Pulsatile or continuous dopaminomimetic strategies in Parkinson's disease.

Calandrella D, Antonini A.

Parkinsonism Relat Disord. 2012 Jan;18 Suppl 1:S120-2. doi: 10.1016/S1353-8020(11)70037-2. Review.

Protective effects of kidney-tonifying Chinese herbal preparation on substantia nigra neurons in a mouse model of Parkinson's disease.

Cai J, Tian Y, Lin R, Chen X, Liu Z, Xie J.

Neural Regen Res. 2012 Feb 25;7(6):413-20. doi: 10.3969/j.issn.1673-5374.2012.06.002.

Ropinirole does not affect plasma arginine vasopressin levels in patients with advanced Parkinson's disease.

Arai M.

Neuro Endocrinol Lett. 2012;33(7):680-3.

Declining quality of life in Parkinson disease before and after diagnosis.

Palacios N, Gao X, Schwarzschild M, Ascherio A.

J Parkinsons Dis. 2012;2(2):153-60. doi: 10.3233/JPD-2012-12083.

A comparison of nine scales to detect depression in Parkinson disease: which scale to use?

Williams JR, Hirsch ES, Anderson K, Bush AL, Goldstein SR, Grill S, Lehmann S, Little JT, Margolis RL, Palanci J, Pontone G, Weiss H, Rabins P, Marsh L.

Neurology. 2012 Mar 27;78(13):998-1006. doi: 10.1212/WNL.0b013e31824d587f.

Chelators in the treatment of iron accumulation in Parkinson's disease.

Mounsey RB, Teismann P.

Int J Cell Biol. 2012;2012:983245. doi: 10.1155/2012/983245.

Aging-associated alteration of telomere length and subtelomeric status in female patients with Parkinson's disease.

Maeda T, Guan JZ, Koyanagi M, Higuchi Y, Makino N.

J Neurogenet. 2012 Jun;26(2):245-51. doi: 10.3109/01677063.2011.651665.

The immunological challenges of cell transplantation for the treatment of Parkinson's disease.

Piquet AL, Venkiteswaran K, Marupudi NI, Berk M, Subramanian T.

Brain Res Bull. 2012 Jul 1;88(4):320-31. doi: 10.1016/j.brainresbull.2012.03.001. Review.

Huntingtin aggregation kinetics and their pathological role in a Drosophila Huntington's disease model.

Weiss KR, Kimura Y, Lee WC, Littleton JT.

Genetics. 2012 Feb;190(2):581-600. doi: 10.1534/genetics.111.133710.

Intracerebroventricular transplanted bone marrow stem cells survive and migrate into the brain of rats with Parkinson's disease.

Gu P, Zhang Z, Cui D, Wang Y, Ma L, Geng Y, Wang M.

Neural Regen Res. 2012 May 5;7(13):978-84. doi: 10.3969/j.issn.1673-5374.2012.13.003.

Longitudinal analysis of the behavioural phenotype in R6/1 (C57BL/6J) Huntington's disease transgenic mice.

Brooks SP, Janghra N, Workman VL, Bayram-Weston Z, Jones L, Dunnett SB.

Brain Res Bull. 2012 Jun 1;88(2-3):94-103. doi: 10.1016/j.brainresbull.2011.01.010.